Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.580
+0.020 (1.28%)
Jan 23, 2025, 12:30 PM EST - Market open
Quince Therapeutics Employees
Quince Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 11 or 52.38% compared to the previous year.
Employees
32
Change (1Y)
11
Growth (1Y)
52.38%
Revenue / Employee
n/a
Profits / Employee
-$1,664,500
Market Cap
69.52M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
QNCX News
- 2 months ago - Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire
- 2 months ago - Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting - Business Wire
- 3 months ago - Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 5 months ago - Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 5 months ago - Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex - Seeking Alpha
- 5 months ago - Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - Business Wire
- 5 months ago - Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - Business Wire